Eligible participants will be administered inclacumab or placebo intravenous (IV) every 12 weeks.~The total duration of treatment for each participant will be 48 weeks.~Participants that complete the study through Week 48 will be provided the opportunity to enroll in an open-label extension (OLE) study.
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.